Juraj Ahel
@juraj-ahel.bsky.social
43 followers 86 following 3 posts
Posts Media Videos Starter Packs
Reposted by Juraj Ahel
ahellab.bsky.social
The application deadline has been extended for a postdoc position in our lab until August 22. Please enquire/apply if you are interested in ADP-ribosylation, ubiquitination, genome stability or immunity.
my.corehr.com/pls/uoxrecru...
'
my.corehr.com
Reposted by Juraj Ahel
wiringthebrain.bsky.social
This isn't a coincidence, IMO. The fly community is generally super rigorous - because there are so many tools and techniques available, people expect you to really nail things in order to get published (and keep getting funded)
juraj-ahel.bsky.social
What my brother @aheljo.bsky.social works on nowadays :)
marcbuhler.bsky.social
Remodeling Activity of ChAHP Restricts Transcription Factor Access to Chromatin
Transcription in eukaryotes is regulated by chromatin-based mechanisms that control nucleosome occupancy, chromatin modifications, and transcription factor binding. We have previously shown that the transcription factor ADNP forms the ChAHP complex with the chromatin remodeler CHD4 and HP1 proteins, acting as a site-specific regulator of transcription and antagonist of CTCF binding. However, the molecular basis of these functions remained unclear. Here, we demonstrate that the CHD4 subunit is essential to antagonize CTCF and silence transcription of transposons, while HP1 proteins are dispensable. Although the remodeling activity of CHD4 is not required for ChAHP chromatin association, it is critical for both transposon repression and CTCF antagonism. Our findings support a model wherein ADNP recruits chromatin remodeling activity in a sequence-specific manner, enabling transcriptional control and local modulation of chromatin architecture. ### Competing Interest Statement The Friedrich Miescher Institute for Biomedical Research (FMI) receives significant financial contributions from the Novartis Research Foundation. Published research reagents from the FMI are shared with the academic community under a Material Transfer Agreement (MTA) having terms and conditions corresponding to those of the UBMTA (Uniform Biological Material Transfer Agreement). Novartis Research Foundation, n.a. Swiss National Science Foundation, grant 310030_188835
www.biorxiv.org
Reposted by Juraj Ahel
ahellab.bsky.social
A postdoc position is available in our lab to study ADP-ribosylation and ubiquitylation signalling! We are looking for someone with experience in structural biology and biochemistry. The application deadline is June 20th.
my.corehr.com/pls/uoxrecru...
'
my.corehr.com
Reposted by Juraj Ahel
msuskiewicz.bsky.social
Happy to share a new little paper from our team - by @origichals.bsky.social et al. It describes a strategy to make SUMO1 more crystallisable by fusing it with a helper domain. Check out the nice ITC showing it still binds to SIM motifs. We are now working on co-crystallisation with SIM peptides.
onlinelibrary.wiley.com
Reposted by Juraj Ahel
juraj-ahel.bsky.social
Happy that my work on RNF213 has been published as a part of doi.org/10.1038/s414...!

Many thanks to all the groups involved:
@clausenlab.bsky.social
@e3chembio.bsky.social
@fletcherlab.bsky.social

Have a look at the summary from Fletcher lab for an insider perspective of the paper's history:
juraj-ahel.bsky.social
"If an experiment fails, our first thought is usually "did I do something wrong?"" - what's sadly often missing is asking the same question when the experiment "succeeds", i.e. gives the wished-for result. There's a severe lack of (self-)skepticism in this line of work once it gets 'exciting'. :)